Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00272051 | XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy | PHASE3 | COMPLETED | 620 | — | — | Jul 1, 2002 | May 1, 2004 | Sep 13, 2006 | - | — |
| Name | Type | Description |
|---|---|---|
| SR57746A | DRUG | - |
Inclusion Criteria: * Histologically or cytologically proven adenocarcinoma of the colon or the rectum * age \> 18 years * WHO performance status : 0,1,2 * Signed written informed consent prior to study entry * Disease stage : metastatic disease not amenable to potentially curative treatment (eg : ...